Tyme Technologies, Inc. (TYME): Price and Financial Metrics

Tyme Technologies, Inc. (TYME): $1.14

0.06 (+5.56%)

POWR Rating

Component Grades













TYME Stock Price Chart Interactive Chart >

Price chart for TYME

TYME Price/Volume Stats

Current price $1.14 52-week high $4.99
Prev. close $1.08 52-week low $0.85
Day low $1.08 Volume 2,186,000
Day high $1.14 Avg. volume 7,059,046
50-day MA $1.09 Dividend yield N/A
200-day MA $1.51 Market Cap 196.32M

Tyme Technologies, Inc. (TYME) Company Bio

Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.

TYME Latest News Stream

Event/Time News Detail
Loading, please wait...

TYME Latest Social Stream

Loading social stream, please wait...

View Full TYME Social Stream

Latest TYME News From Around the Web

Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Every investor in Tyme Technologies, Inc. ( NASDAQ:TYME ) should be aware of the most powerful shareholder groups...

Yahoo | September 13, 2021

TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBT

Business Wire | September 2, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | August 24, 2021

Nothing seems to bother Tyme Technologies (NASDAQ:TYME)

Earnings results for Tyme Technologies , Analyst Opinion on Tyme Technologies , Earnings and Valuation of (NASDAQ:TYME), Stock market Insights & financial analysis, Best stock to invest, Investment Idea, The post Nothing seems to bother Tyme Technologies (NASDAQ:TYME) appeared first on .

Stock Market Daily | August 10, 2021

TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its fiscal first quarter ended June 30, 2021. Fiscal First Quarter 2022 Business and Recent Highlights: Completed strategic review and identified clinical priorities with a focus on metastatic hormone receptor positive, human epidermal growth factor receptor 2 ne

Business Wire | August 10, 2021

Read More 'TYME' Stories Here

TYME Price Returns

1-mo 3.64%
3-mo -10.24%
6-mo -35.96%
1-year 19.51%
3-year -58.99%
5-year -67.89%
YTD -6.56%
2020 -12.86%
2019 -62.06%
2018 -42.16%
2017 70.13%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7468 seconds.